Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Filipits, M; Nielsen, TO; Rudas, M; Greil, R; Stöger, H; Jakesz, R; Bago-Horvath, Z; Dietze, O; Regitnig, P; Gruber-Rossipal, C; Müller-Holzner, E; Singer, CF; Mlineritsch, B; Dubsky, P; Bauernhofer, T; Hubalek, M; Knauer, M; Trapl, H; Fesl, C; Schaper, C; Ferree, S; Liu, S; Cowens, JW; Gnant, M; Austrian Breast and Colorectal Cancer Study Group.
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
Clin Cancer Res. 2014; 20(5):1298-1305
Doi: 10.1158/1078-0432.CCR-13-1845
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Bauernhofer Thomas
- Regitnig Peter
- Stöger Herbert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To assess the prognostic value of the PAM50 risk-of-recurrence (ROR) score on late distant recurrence (beyond 5 years after diagnosis and treatment) in a large cohort of postmenopausal, endocrine-responsive breast cancer patients. The PAM50 assay was performed on formalin-fixed paraffin-embedded whole-tumor sections of patients who had been enrolled in the Austrian Breast and Colorectal Cancer Study Group Trial 8 (ABCSG-8). RNA expression levels of the PAM50 genes were determined centrally using the nCounter Dx Analysis System. Late distant recurrence-free survival (DRFS) was analyzed using Cox models adjusted for clinical and pathologic parameters. PAM50 analysis was successfully performed in 1,246 ABCSG-8 patients. PAM50 ROR score and ROR-based risk groups provided significant additional prognostic information with respect to late DRFS compared with a combined score of clinical factors alone (ROR score: ΔLRχ(2) 15.32, P < 0.001; ROR-based risk groups: ΔLRχ(2) 14.83, P < 0.001). Between years 5 and 15, we observed an absolute risk of distant recurrence of 2.4% in the low ROR-based risk group, as compared with 17.5% in the high ROR-based risk group. The DRFS differences according to the PAM50 ROR score were observed for both node-positive and node-negative disease. PAM50 ROR score and ROR-based risk groups can differentiate patients with breast cancer with respect to their risk for late distant recurrence beyond what can be achieved with established clinicopathologic risk factors. ©2014 AACR
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Antineoplastic Agents, Hormonal - therapeutic use
- Breast Neoplasms - diagnosis
- Breast Neoplasms - drug therapy
- Breast Neoplasms - genetics
- Breast Neoplasms - mortality
- Female -
- Follow-Up Studies -
- Gene Expression Profiling -
- Humans -
- Middle Aged -
- Neoplasm Metastasis -
- Neoplasm Recurrence, Local -
- Neoplasm Staging -
- Postmenopause -
- Prognosis -
- Treatment Outcome -